



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

11/6

Attorney Docket No.: PENN-0749

Inventors: Muzykantov et al.

Serial No.: 09/762,023

Filing Date: June 28, 2001

Examiner: DiBrino, Marianne NMN

Group Art Unit: 1644

Title: Targeting and Prolonging Association of
Drugs to the Luminal Surface of the
Pulmonary Vascular Endothelial Cells

RECEIVED
APR 21 2003
TECH CENTER 1600/2900

"Express Mail" Label No. EV348513002US
Date of Deposit April 15, 2003

I hereby certify that this paper is being deposited
with the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the
U.S. Patent & Trademark Office, Box Amendment,
P.O. Box 2327, Arlington, VA 22202.

By Kathleen A. Tyrell
Typed Name: Kathleen A. Tyrell, Registration No. 38,350

U.S. Patent & Trademark Office
Box Amendment, P.O. Box 2327
Arlington, VA 22202

Reply under 37 C.F.R. § 1.111

This is a reply to the Office Action mailed January 16, 2003
setting a three (3) month statutory period for response. Please
enter the following amendments and remarks into the record.

PENN-0749



CERTIFICATE OF EXPRESS MAILING


"Express Mail" Label No. **EV348513002US**

Date of Deposit **April 15, 2003**

RECEIVED
APR 21 2003
TECH CENTER 1600/2900


I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the "BOX AMENDMENT", U.S. Patent & Trademark Office, P.O. Box 2327, Arlington, VA 22202.

- 1) Amendment Transmittal Letter (2 copies);
- 2) Reply under 37 C.F.R. § 1.111;
- 3) Publication by Murciano et al. (*Am. J. Crit. Care*, **October 1, 2001** 163:1295-1302;
- 4) Publication by Murciano et al. (*Blood*, **2003** MS 2002-09-2853); and
- 5) Return Post Card.


KATHLEEN A. TYRRELL

04-17-03

1644

AMENDMENT TRANSMITTAL LETTER (Small Entity)			Docket No. PENN-0749		
Applicant(s): Muzykantov et al.					
Serial No. 09/762,023	Filing Date June 28, 2001	Examiner M. DiBrino		Group Art Unit 1644	
Invention: TARGETING AND PROLONGING ASSOCIATION OF DRUGS TO THE LUMINAL SURFACE OF THE PULMONARY VASCULAR ENDOTHELIAL CELLS					
<u>TO THE ASSISTANT COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is an amendment in the above-identified application.					
<input checked="" type="checkbox"/> Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted. <input type="checkbox"/> A verified statement to establish Small Entity status under 37 FR 1.27 is enclosed.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	2 -	20 =	0 x	\$9.00	\$0.00
INDEP. CLAIMS	1 -	3 =	0 x	\$42.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ A duplicate copy of this sheet is enclosed. <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-1619 A duplicate copy of this sheet is enclosed. <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.					
Signature  Kathleen A. Tyrrell Reg. No. 38,350 Licata & Tyrrell P.C. 66 E. Main Street Marlton, NJ 08053 Tel: 856-810-1515 Fax: 856-810-1454			Dated: April 15, 2003		
<div style="border: 1px solid black; padding: 5px;"> I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231. </div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"> Signature of Person Mailing Correspondence </div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"> Typed or Printed Name of Person Mailing Correspondence </div>					
cc:					

